Vaccination and the role of capsular polysaccharide antibody in prevention of recurrent meningococcal disease in late complement component-deficient individuals.
This study sought to quantitate the response of late complement component-deficient (LCCD) individuals to the meningococcal vaccine, to examine antibody persistence, and to investigate the contribution of these antibodies to meningococcal killing in complement- and phagocyte-dependent bactericidal assays. The mean concentration of antibody to group A and C capsular polysaccharide after vaccination was similar in 8 LCCD, 11 family members, and 7 unrelated normal individuals. LCCD individuals had a greater percentage decline in antibody concentration to group C polysaccharide and had lower concentrations of antibody to group Y polysaccharide 2.0-2.5 years after vaccination than did normal and heterozygous deficient persons. Antibody to subcapsular antigens was minimally effective in mediating complement-dependent killing and had no effect in the opsonophagocytic assay. In contrast, antibody to capsular polysaccharide promoted meningococcal killing in both assays. These data support vaccination as a preventive measure in LCCD individuals and lend credence to the idea that these individuals are critically dependent on capsular antibody for protection against meningococcal disease.
Andreoni
J
J
Department of Internal Medicine, VA Medical Center, Iowa City.
Käyhty
H
H
Densen
P
P
D000328:Adult; D000907:Antibodies, Bacterial / Q000276:immunology; D001428:Bacterial Vaccines / Q000627:therapeutic use*; D003184:Complement C7 / Q000172:deficiency*; D006801:Humans; D007153:Immunologic Deficiency Syndromes / Q000150:complications / Q000276:immunology; D008297:Male; D008589:Meningococcal Infections / Q000150:complications / Q000517:prevention & control*; D011134:Polysaccharides / Q000276:immunology*
D000907:Antibodies, Bacterial; D001428:Bacterial Vaccines; D003184:Complement C7; D011134:Polysaccharides